Available Until 9/27/2022

Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 1A-B (Cert # L229128)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 02/23/2022
Content Release Date: 03/23/2022
Expiration Dates: 09/27/2022
Activity Type: Application-based
CE Credits: 8 contact hours
Activity Fee: $160 (ASHP member); $215 (non-member) 

The Home Study Syllabus is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of two online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice.

Learners will be required to review the content of the articles and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.  

The American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Research Design, Statistics, and Evaluating Oncology Literature
  • Upper Gastrointestinal Carcinoma
  • Oncology Practice Management
  • Bladder, Renal, and Testicular Cancers
  • Adult Sarcoma
  • Chronic Leukemias
  • Pediatric Malignancies
  • Pharmacogenomics

Learning Activity

ACPE Number

Contact Hours

Assessment Pass Point

Oncology Home Study Syllabus Module 1A: Research Design and Statistics and Evaluating Oncology Literature, Upper Gastrointestinal Carcinoma, Oncology Practice Management, and Bladder, Renal, and Testicular Cancers

0204-9999-22-952-H01-P

4.0

80%

Oncology Home Study Syllabus Module 1B: Adult Sarcoma, Chronic Leukemias, Pediatric Malignancies, and Pharmacogenomics

0204-9999-22-953-H01-P

4.0

75%

Oncology Home Study Syllabus Module 1A: Research Design and Statistics, Upper Gastrointestinal Carcinoma, Oncology Practice Management, and Bladder, Renal, and Testicular Cancers

0204-9999-22-952-H01-P

Mauri L, D’Agostino Sr RB. Challenges in the design and interpretation of noninferiority trials. N Engl J Med. 2017;377:1357-67. 

Agnelli G, Becattini C, Meyer G et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599-607.

Learning Objectives:

  • Evaluate a noninferiority trial with regard to study design and methods.
  • Critique a noninferiority trial with respect to statistical analyses.
  • Modify and evaluate educational materials for oncology therapies based on results of a noninferiority trial.

Kelly RJ, Ajani JA, Kuzdzal J et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021; 384:1191-203.

Learning Objectives:

  • Describe the CheckMate 577 trial of adjuvant nivolumab for patients with resected esophageal or gastroesophageal junction (EGJ) cancer.
  • Develop recommendations for the use of adjuvant nivolumab in patients with resected esophageal or EGJ cancer based on the results of CheckMate 577.
  • Select appropriate patients to receive adjuvant nivolumab based on the results of CheckMate 577.

Durr P, Schlichtig K, Kelz C et al. The randomized AMBORA trial: impact of pharmacological/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents. J Clin Oncol. 2021; 39:1983-94.

Learning Objectives:

  • Describe the study intervention of oncology pharmacy clinical services for patients receiving oral oncolytic therapy.
  • Evaluate the impact of various pharmaceutical care interventions for patients receiving oral anticancer therapy in the outpatient setting.
  • Develop recommendations for the implementation of oncology clinical pharmacy services in patients receiving oral oncolytic therapy. 

Powles T, Park SH, Voog E et al. Avelumab maintenance therapy for advanced or metastatic urothelial cancer. N Engl J Med. 2020; 383:1218-30.

Learning Objectives:

  • Apply the outcomes of Powles et al. (JAVELIN Bladder 100) to patients with newly diagnosed bladder cancer.
  • Summarize the strengths and weaknesses of the design and methods used by Powles et al.
  • Counsel patients on the expected benefits and toxicities of avelumab maintenance therapy based on analysis of JAVELIN Bladder 100.

Oncology Home Study Syllabus Module 1B: Adult Sarcoma, Chronic Leukemias, Pediatric Malignancies, and Pharmacogenomics

0204-9999-22-953-H01-P

Kang YK, George S, Jones RL et al. Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open – label phase III study. J Clin Oncol. 2021; 39:3128-39.

Learning Objectives:

  • Describe the VOYAGER trial of avapritinib for patients with advanced, metastatic gastrointestinal stromal tumors (GIST).
  • Develop recommendations for the use of avapritinib in patients with advanced, metastatic GIST based on the results of the VOYAGER trial.
  • Select appropriate patients to receive avapritinib based on the results of the VOYAGER trial.

 

Sharman JP, Egyed M, Jurczak W et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet. 2020; 395:1278-91.

Learning Objectives:

  • Describe a study of acalabrutinib with or without obinutuzumab for the first-line treatment of chronic lymphocytic leukemia.
  • Develop recommendations for the use of acalabrutinib with or without obinutuzumab in the first-line treatment of chronic lymphocytic leukemia.

 

Dunsmore KP, Winter SS, Devidas M et al.  Children’s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020; 38:3282-93.

Learning Objectives:

  • Describe the study of nelarabine for T-cell acute lymphoblastic leukemia in children and young adults.
  • Develop recommendations for the use of nelarabine in patients with T-cell acute lymphoblastic leukemia.

 

Awad MM, Liu S, Rybkin II et al.  Acquired resistance to KRAS G12C inhibition in cancer. N Engl J Med. 2021; 384:2382-93

Learning Objectives:

  • Describe the study assessing acquired resistance mechanisms following treatment with adagrasib in patients with KRAS G12C mutated solid tumors.
  • Develop recommendations for the use of adagrasib in patients with KRAS G12C mutated solid tumors.

John Bossaer, Pharm.D., BCPS, BCOP
Professor
Bill Gatton College of Pharmacy at ETSU
Johnson City, Tennessee

Courtney C. Cavalieri, Pharm.D., BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Karen M. Fancher, Pharm.D., BCOP*
Associate Professor of Pharmacy Practice/ Clinical Pharmacy Specialist - Oncology
Duquesne University School of Pharmacy/UPMC Passavant Hospital
Pittsburgh, Pennsylvania

Christopher Fausel, Pharm.D., M.H.A., BCOP
Clinical Specialist – Precision Medicine
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana

Elyse MacDonald, Pharm.D., M.S., BCPS
Director, Pharmacy Services, Investigational Drug Service
Stanford Health Care
Palo Alto, California

Janelle Mann, Pharm.D., BCOP
Clinical Oncology Pharmacist/Manger, Clinical Pharmacy Services
Alvin J. Siteman Cancer Center/Washington University School of Medicine in St. Louis
St. Louis, Missouri

Danielle Roman, Pharm.D., BCOP*
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Christine M. Walko, Pharm.D., BCOP, FCCP*
Associate Member, Individualized Cancer Management
H. Lee Moffitt Cancer Center
Tampa, Florida

Jennifer Young, Pharm.D., BCOP
Clinical Pharmacy Specialist – Pediatric Oncology
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

*Content Matter Experts

Angela T. Cassano, Pharm.D., BCPS, FASHP
Susan R. Dombrowski, M.S., RPh

Susan Abeln, BSPharm, RPh, BCOP
Nada Adel, BCOP, BCPS
Mohammed Alfar, Bsc, BCOP
Pamiz Alibhai, Pharm.D., MBA, BCOP
Jonathan Angus, Pharm.D., BCOP
Nwaka Anosike, Pharm.D., BCOP
Allison Bass, Pharm.D., BCOP
Mollie Beck, Pharm.D., BCOP
Patricia Bollendorf-Perez, BSPharm
Janet Bramell, Pharm.D., BCPS, BCOP
Nicole Brunette, Pharm.D. BCPS BCOP
Chris Campbell, Pharm.D., BCOP
Alexis Chapman, Pharm.D., BCOP
Debra Chibroski, Pharm.D., RPh, BCOP
Nicholas Chow, Pharm.D., BCOP
Jill Comeau, Pharm.D., BCOP
Phuong Dao, Pharm.D., BCOP
Raymond DeMatteo, Pharm.D., BCOP
Alan Fisher, Pharm.D., BCOP
Bryan Fitzgerald, Pharm.D., BCOP
Sara Fleszar, Pharm D, BCOP
Dmitri Gordon, Pharm.D., BCOP
Benjamin Gruseck, Pharm.D., BCOP
Christina Haaf, Pharm.D., BCOP
Elisabeth Hebert, B.Pharm, M.Sc
Jerline Hsin, Pharm.D., BCOP, BCPS
Brooke Hueftle, Pharm.D.
Caren Hughes, Pharm.D., BCOP
Christine Hughes, Pharm.D., MBA, BCOP
Amy Kamien, Pharm.D., BCOP
Natalie Kamiyama, Pharm.D., BCOP
Minhee Kang, Pharm.D., BCOP, BCPS
Erin Kelley, Pharm.D., BCOP
Elle Kim, RPh, BCPS, BCOP
Tracy Joy King, Pharm.D., BCOP, BCPS
Polly Kintzel, Pharm.D., BCPS, BCOP
Tiffany Knoll, MS, Pharm.D., BCOP
Pohung Lin, Pharm.D., BCOP, BCPS
Robert Luschen, Pharm.D., BCOP
Morgan Mace, Pharm.D., BCOP
Claire Mach, Pharm.D., BCOP
Edward McLean, Pharm.D., BCOP, BCSCP
Jessie Modlin, Pharm.D., BCOP
Sindhu Nair, Pharm.D., BCOP
Carolyn Oxencis, Pharm.D., BCOP
Jiyeon Park, Pharm.D., BCOP
Jooyoung Park, Pharm.D., BCOP
Pragna Patel, Pharm.D., BCOP
Justine Preedit, Pharm.D., BCOP
Mohammad Rattu, Pharm.D., BCOP, BCPS, BCGP
Forrest Ridgway, Pharm.D., BCPS, BCOP
Paula Sayegh, Pharm.D., BCPS, BCOP
Shreya Shah, Pharm.D., BCOP
Bethany Sibbitt, Pharm.D., BCOP
Anne Spengler, Pharm.D., BCOP
Barbara Yim, Pharm.D., BCOP
Spencer Yingling, Pharm.D., BCOP
Wai Chung (Olivia) Yiu, MPharm
Carolnn Yong, Pharm.D., BCOP, BCPS
Crystal Young, Pharm.D., BCOP
Carrie Zhao, Pharm.D.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Karen Fancher: Consultant, AstraZeneca, LP

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP and ACCP.